GreenLight Biosciences Holdings PBC (GRNA) Fundamental Analysis & Valuation

NASDAQ:GRNA • US39536G1058

Current stock price

0.2995 USD
0 (-0.03%)
At close:
0.2995 USD
0 (0%)
After Hours:

This GRNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GRNA Profitability Analysis

1.1 Basic Checks

  • In the past year GRNA has reported negative net income.
  • In the past year GRNA has reported a negative cash flow from operations.
GRNA Yearly Net Income VS EBIT VS OCF VS FCFGRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • GRNA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRNA Yearly ROA, ROE, ROICGRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -2K -4K -6K -8K -10K

1.3 Margins

  • GRNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRNA Yearly Profit, Operating, Gross MarginsGRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. GRNA Health Analysis

2.1 Basic Checks

  • GRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GRNA has more shares outstanding
  • GRNA has a better debt/assets ratio than last year.
GRNA Yearly Shares OutstandingGRNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
GRNA Yearly Total Debt VS Total AssetsGRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M

2.2 Solvency

  • GRNA has an Altman-Z score of -9.56. This is a bad value and indicates that GRNA is not financially healthy and even has some risk of bankruptcy.
  • GRNA's Altman-Z score of -9.56 is on the low side compared to the rest of the industry. GRNA is outperformed by 80.98% of its industry peers.
  • GRNA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • GRNA has a worse Debt to Equity ratio (0.49) than 76.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -9.56
ROIC/WACCN/A
WACC8.59%
GRNA Yearly LT Debt VS Equity VS FCFGRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M -100M -150M

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that GRNA should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.21, GRNA is not doing good in the industry: 90.15% of the companies in the same industry are doing better.
  • GRNA has a Quick Ratio of 1.21. This is a normal value and indicates that GRNA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of GRNA (1.21) is worse than 89.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
GRNA Yearly Current Assets VS Current LiabilitesGRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GRNA Growth Analysis

3.1 Past

  • The earnings per share for GRNA have decreased by -5.79% in the last year.
  • Looking at the last year, GRNA shows a very strong growth in Revenue. The Revenue has grown by 577.34%.
  • The Revenue has been growing by 31.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.19%
Revenue 1Y (TTM)577.34%
Revenue growth 3Y31.22%
Revenue growth 5YN/A
Sales Q2Q%1386.38%

3.2 Future

  • GRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.95% yearly.
  • GRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.83% yearly.
EPS Next Y26.28%
EPS Next 2Y12.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year167.93%
Revenue Next 2Y157.83%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GRNA Yearly Revenue VS EstimatesGRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M
GRNA Yearly EPS VS EstimatesGRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. GRNA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GRNA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRNA Price Earnings VS Forward Price EarningsGRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRNA Per share dataGRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • GRNA's earnings are expected to grow with 12.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.95%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRNA Dividend Analysis

5.1 Amount

  • GRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GRNA Fundamentals: All Metrics, Ratios and Statistics

GreenLight Biosciences Holdings PBC

NASDAQ:GRNA (7/21/2023, 8:00:02 PM)

After market: 0.2995 0 (0%)

0.2995

0 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11
Earnings (Next)08-14
Inst Owners0.03%
Inst Owner Change0%
Ins Owners16.91%
Ins Owner Change0%
Market Cap45.43M
Revenue(TTM)10.34M
Net Income(TTM)-157.32M
Analysts45.71
Price Target0.46 (53.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.16%
Min EPS beat(2)2.16%
Max EPS beat(2)2.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)179.87%
Min Revenue beat(2)85.23%
Max Revenue beat(2)274.51%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-80.43%
EPS NQ rev (1m)-58.24%
EPS NQ rev (3m)-7.82%
EPS NY rev (1m)-14.11%
EPS NY rev (3m)-14.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)69.05%
Revenue NY rev (3m)69.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.39
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.07
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 335.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -9.56
F-Score4
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.19%
EPS Next Y26.28%
EPS Next 2Y12.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)577.34%
Revenue growth 3Y31.22%
Revenue growth 5YN/A
Sales Q2Q%1386.38%
Revenue Next Year167.93%
Revenue Next 2Y157.83%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.89%
OCF growth 3YN/A
OCF growth 5YN/A

GreenLight Biosciences Holdings PBC / GRNA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GreenLight Biosciences Holdings PBC (GRNA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GRNA.


What is the valuation status for GRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to GreenLight Biosciences Holdings PBC (GRNA). This can be considered as Overvalued.


How profitable is GreenLight Biosciences Holdings PBC (GRNA) stock?

GreenLight Biosciences Holdings PBC (GRNA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GreenLight Biosciences Holdings PBC?

The Earnings per Share (EPS) of GreenLight Biosciences Holdings PBC (GRNA) is expected to grow by 26.28% in the next year.